|
|
|
|
| Europe |
 |
|
A Long Summer of Drug Pricing Tension Looms |
In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector
... /Read more/ |
|
|
|
|
|
| Industry update |
| //Anne Cunningham joined Research Partnership’s European division as a Director at the company’s global head office in London. Morten Anderson also joined the company’s specialist quantitative team as an Associate Director.//Axovant Sciences (Basel, Switzerland) has made several key senior management hires to its executive team. Stephen Mohr joined the as General Counsel, Eric Floyd, Ph.D., as Senior Vice President, Regulatory Affairs; Thomas Templeman, Ph.D., as Senior Vice President, Pharmaceutical Operations and Quality Assurance; Mark Wadley as Senior Vice President, U.S. business; and Samina Bari as Vice President, corporate communications. In addition, the company appointed current executive team member Shankar Ramaswamy, M.D., to a new role as Vice President, Global Medical Affairs. //Silence Therapeutics (London, UK) hired Torsten Hoffmann as Chief Operating Officer.//Summit Therapeutics (Oxford, UK) reported that Dr. David Roblin, who recently became Chief Operating Officer and President of R&D, will expand his role to become Chief Medical Officer. Summit also appointed Anne Heatherington, Ph.D, as Head of Clinical Development and Quantitative Sciences and Dave Powell, Ph.D, as Head of Research. //
SYGNIS (Madrid, Spain and Heidelberg, Germany) announced that Dr. Heikki Lanckriet (previously Co-CEO) will become sole CEO and will also retain his role as Chief Scientific Officer. // |
|
|
|
